nesuparib (JPI-547) / Jeil  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nesuparib (JPI-547) / Jeil
NCT05475184: A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Not yet recruiting
2
58
NA
JPI-547
Onconic Therapeutics Inc.
Ovarian Cancer
11/24
06/25

Download Options